Phil Reason, Instem’s chief executive, talks through the latest results for the pharma services group with Proactive.
Twelve per cent organic growth was 'tremendous' he says, but it was the three acquisitions last year that really transformed the scope of the business.
We are doing what the pharma sector really needs, he adds, and that is to reinvent the way it does R&D.